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INTRODUCTION
The human interactome has been estimated to cover ~400,000 
protein–protein interactions (PPIs), indicating an area of high 
complexity and organization, which may hide answers to many 
unsolved questions in biology. In addition, PPIs provide a wealth 
of opportunities for therapeutic intervention in a broad range of 
disease conditions. For long, the typical large and flat nature of 
protein interaction surfaces, often missing clear features (such 
as pockets, grooves, or clefts) that could act as potential docking 
sites for small molecule inhibitors, has withheld researchers from 
exploiting PPIs as drug targets.1 In those cases where such features 
are present, the structural complexity of the interface often poses 
an additional challenge; the binding epitopes of PPI surfaces are 
often created by secondary and tertiary protein structures, pre-
cluding the use of a linear peptide sequence as a template for mod-
eling a new therapeutic molecule, e.g., a small molecule peptide 
mimetic.2 Moreover, the lack of natural small molecule ligands 
that could serve as an alternative starting point for drug design 
has been perceived as another major obstacle.1 With the discovery 
of so-called “hot spots” in PPI interfaces, well-defined regions that 
contribute most of the binding energy, it became feasible to target 
a broader range of PPIs with small molecule drugs.3 The identifi-
cation of hot spots has enabled researchers to identify molecules 
that interact at these sites, thus interfering with PPIs and the 
downstream pathways they mediate. Small molecule compounds 
that modulate PPIs can directly target the protein interaction 
interface, resulting in its disruption or stabilization (orthosteric 
PPI inhibitors or stabilizers). Alternatively, PPI-modulating com-
pounds can bind to a neighboring site on one of the interacting 
proteins and inhibit or enhance the PPI by changing its conforma-
tion (allosteric PPI inhibitors or stabilizers) (Figure 1).4,5
Technological progress has played a key role in the identifi-
cation of small molecules modulators of PPIs. Indeed, sensitive 
screening approaches are required to detect the typically low affin-
ity interaction with a protein interaction interface of initial small 
molecule hits. High-throughput screening-compatible assays 
that have yielded useful starting points for chemical optimiza-
tion include fluorescence resonance energy transfer, amplified 
luminescent proximity homogeneous assay screen (AlphaScreen; 
PerkinElmer), surface plasmon resonance, and fluorescence polar-
ization.1,6 Alternatively, PPI inhibitor discovery programs driven 
by a structure-based approach have proven successful.7 Structural 
information about the PPI interface—obtained through X-ray 
crystallography, nuclear magnetic resonance or homology mod-
eling—enables in silico screening of virtual compound libraries. 
In a next stage, promising hits are synthesized and tested in an 
appropriate protein binding or interaction assay.
Applying this highly diverse set of discovery tools, potent PPI 
modulators are being developed for a broad spectrum of protein 
complexes and several of these have already progressed into clini-
cal trials. In this review, we provide an overview of the applica-
tion range of PPI modulators and present a selection of promising 
compounds that are currently making their way through  (pre-)
clinical development.
THE “YIN” FACE OF PPIs – INHIBITION OF PPIs IN 
DRUG DESIGN
Interactions involved in the cell cycle pathway as 
possible therapeutic targets for cancer
MDM2/p53. One of the best-studied PPIs in cancer research is 
the interaction of murine double minute 2 (MDM2) with p53. 
The transcription factor p53 plays a crucial role in cell cycle regu-
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Protein–protein interactions (PPIs) underlie most biological processes. An increasing interest to investigate the 
unexplored potential of PPIs in drug discovery is driven by the need to find novel therapeutic targets for a whole 
range of diseases with a high unmet medical need. To date, PPI inhibition with small molecules is the mechanism 
that has most often been explored, resulting in significant progress towards drug development. However, also 
PPI stabilization is gradually gaining ground. In this review, we provide a focused overview of a number of PPIs 
that control critical regulatory pathways and constitute targets for the design of novel therapeutics. We discuss 
PPI-modulating small molecules that are already pursued in clinical trials. In addition, we review a number of PPIs 
that are still under preclinical investigation but for which preliminary data support their use as therapeutic targets.
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lation, apoptosis, DNA repair, senescence, angiogenesis, and in-
nate immunity.8,9 p53 is a potent tumor suppressor and in 50% of 
human cancers, its antitumor activity is impaired due to muta-
tions within the p53 gene.10 In most other human cancers, p53 
retains its wild-type status but its function as a tumor suppressor 
is compromised by multiple intracellular mechanisms. MDM2 
or HDM2 in human is the major inhibitor of p53. MDM2 binds 
directly to p53, resulting in a repressed p53 transactivation ac-
tivity, enhanced nuclear export of p53, and degradation of p53 
by ubiquitination through its E3 ligase activity (Figure  2).11–13 
Additionally, overexpression of MDM2 in human tumors corre-
lates with poor clinical prognosis and poor treatment response to 
current cancer treatments. Amplification of MDM2 was found in 
7% of human cancers following an analysis of 28 different cancer 
types, while amplification of MDM2 and mutations in the p53 
gene are mutually exclusive.14 For these reasons, it became clear 
that interference with the MDM2/p53 interaction could lead to 
an improved antitumor action of p53 and more efficient antican-
cer treatments. MDM2 and p53 interact via their N-terminal do-
mains,15,16 more specifically via a hydrophobic surface groove in 
MDM2 and three key hydrophobic residues in p53, Phe19, Trp23, 
and Leu26. These residues make up the “hot spot” which was tar-
geted by researchers in an attempt to identify molecules that can 
interrupt this specific interaction.17 Although still an area of active 
research, seven MDM2-p53 inhibitors have progressed to clinical 
trials with impressive results.
In 2004, researchers at Roche (Basel, Switzerland) identified 
the nutlins, a first class of specific and orally active, imidazo-
line-containing compounds that bind to MDM2 by mimicking 
the structure of the p53 peptide and the accompanying in vitro 
data supported cell growth inhibition. Nutlins were identified by 
screening a small molecule diversity library using an surface plas-
mon  resonance-based p53-MDM2 competition assay.18 Further 
chemical optimization, aimed at enhancing binding and pharma-
cokinetics, yielded RG7112 a compound that entered clinical trials 
for sarcoma, myelogenous leukemia, neoplasm, and hematologic 
neoplasm.19 The first promising data with RG7112 in clinical tri-
als emerged in 2012. The results from patients with an MDM2-
amplified liposarcoma showed clear evidence of p53 reactivation 
and cell growth inhibition. Unfortunately, its long-term admin-
istration is correlated with hematologic cytotoxicity, including 
neutropenia and thrombocytopenia.20 The same company synthe-
sized the pyrrolidine-containing compound RG7388, a RG7112 
analogue.21 This molecule has better pharmacological properties 
and can activate p53 more potently than RG7112. Upon oral 
administration, it achieves tumor regression in the SJSA-1 osteo-
sarcoma xenograft model in mice. Currently, RG7388 is ready to 
enter phase 2 clinical trials for the treatment of patients with acute 
myelogenous leukemia, solid tumors, or advanced malignancies 
either as a single agent or in combination with chemotherapeutics 
such as cytarabine, although hematologic adverse effects remain 
dose-limiting.22 Sanofi’s MI-77301 (SAR405838; Sanofi, Paris, 
France) is a  spirooxindole-containing compound that entered 
phase 1 clinical trials to assess its safety, pharmacokinetics, and 
biological activity in patients with advanced tumors.23 Identified 
by using  structure-based approaches to mimic the three key bind-
ing residues of p53, MI-77301 binds to MDM2 with kinetics in the 
nanomolar range.24 Still more molecules are being developed by 
different pharmaceutical companies to target this specific inter-
action (Table 1).25,26 MDM2 inhibitors are used as single agents 
or in combination with traditional chemotherapeutic agents. 
Combined treatment is needed because the MDM2 inhibitors are 
highly selective for MDM2 but not for MDMX, which also inter-
acts directly with p53 and represses its action. Conventional che-
motherapeutics such as irinotecan and doxorubicin can effectively 
downregulate the levels of MDMX and consequently their com-
bination with MDM2 inhibitors effectively treats human cancers 
characterized by high expression of both MDM2 and MDMX. 
Efforts towards the identification of inhibitors of MDMX led to 
the discovery of additional molecules such as RO-5963,27 which 
has high binding affinities to MDM2 as well as MDMX.
The caspase 9, XIAP/BIR3, SMAC system. Apoptosis, or pro-
grammed cell death, is mediated mainly through two different 
pathways, yet these intrinsic and extrinsic pathways culminate in 
the activation of caspases. Caspase-9 is an initiator caspase in the 
intrinsic pathway that dimerizes into a catalytically active form able 
Figure 1 The “hot spot” concept and the rationale for designing PPI 
modulators. Upper panel: an orthosteric small molecule inhibitor binds 
to the interaction interface of two proteins, thereby preventing their 
interaction. An allosteric inhibitor binds to the interacting protein A out-
side of the PPI surface, inducing a conformational change that inhibits 
its association with protein B. Lower panel: similarly, an orthosteric small 
molecule stabilizer binds to the PPI surface and stabilizes the interaction 
between proteins B and C, whereas an allosteric stabilizer changes the 
conformation of protein C so that protein D can bind with higher affin-
ity. PPI, protein–protein interaction.
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Figure 2 Small molecule inhibitors in clinical and preclinical stage interfere with PPIs involved in the apoptosis pathway as an anticancer 
treatment. This scheme illustrates three clinically important PPIs: 1) MDM2/p53; 2) Bcl2, Bcl-XL/Bak, Bax; and 3) IAP/caspases, and their role in the 
apoptosis cascade. In blue, proteins are depicted that are targeted for inhibition by small molecules and in pink their interaction partners that pro-
mote apoptosis. The panels below depict the chemical structures of representative small molecule inhibitors that interfere with the respective PPIs. 
IAP, inhibitor of apoptosis protein; MDM2, murine double minute 2; PPI, protein–protein interaction.
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to cleave and activate procaspase-3 and procaspase-7.28 The inhibi-
tor of apoptosis proteins (IAPs) are overexpressed or constitutively 
activated in tumor cells, resulting in evasion of programmed cell 
death. The XIAP (X-linked IAP) is the most potent caspase inhibi-
tor among the IAP protein family.29 XIAP contains three baculo-
viral inhibitory repeat (BIR) domains and a ring domain. This 
protein interacts with initiator caspase-9 through its BIR3 domain 
and with caspases 3 and 7 through its BIR1/2 domains.30 BIR3 in-
hibits caspase-9 by preventing dimerization, which is required for 
its catalytic activity. The search for new compounds that are able to 
disrupt the XIAP–caspase interaction has attracted attention of the 
scientific community as a promising strategy for cancer treatment.
The natural protein inhibitor of XIAP, SMAC/DIABLO (sec-
ond mitochondrial activator of caspases/direct IAP-binding protein 
Table 1 Modulation of PPIs involved in cancer by small molecule inhibitors
PPI Small molecule Investigation stage Binding affinity Disease condition Reference
MDM2/p53 RG7112 Clinical trials (I) 18 nmol/l Sarcoma, ML, neoplasms 2,19,22
RG7388 Clinical trials (I) 6 nmol/l Solid tumors, AML 2,21,22
MI-77301 Clinical trials (I) 0.88 nmol/l Solid tumors 18,22–24
AMG 232 (AM-8553) Clinical trials (I) 0.6 nmol/l AML, solid tumors, MM, melanoma 22,25
MK-8242 (SCH 900242) Clinical trials (I) NS Solid tumors 22
DS-3032b Clinical trials (I) NS HM, solid tumors, lymphomas 22
CGM097 Clinical trials (I) NS Solid tumors 22
IAP/Smac LCL161 Clinical trials (I,II)a 60 nmol/l Solid tumors, MM 32,33
GDC-0917 Clinical trials (I) 50 nmol/l Solid tumors, lymphoma 2,40
GDC-0152 Clinical trials (I) 14–43 nmol/l Locally advanced or metastatic 
malignancies
2,34,35
SM-406 Clinical trials (I) 2 nmol/l Solid tumors 2,36
Birinapant Clinical trials (II) 1 nmol/l CMML, ovarian cancer, fallopian 
tube, and peritoneal neoplasms
37–39
 SM-1387 Clinical trials (I) 1 nmol/l Solid tumors, lymphomas 40
Bcl2/Bak, Bax Navitoclax Clinical trial (II) 0.4 nmol/l Advanced or metastatic solid 
cancers, lymphoid cancers, CLL
2,43,44
ABT-199 Clinical trial (I) 0.01 nmol/l Non-Hodgkin’s lymphoma, AML, 
CLL, MM, SLL
46,47
Obatoclax Clinical trial (II) 0.22 nmol/l Solid tumors, HM 48
Mcl1/Bim A-1210477 Preclinical 0.454 nmol/l Cancer 51
Bromodomain/histones (+)-JQ1 Preclinical 49 nmol/l NUT midline sarcoma, AML, MM 54,55
I-BET762 Clinical trial (I) 630 nmol/l NUT midline carcinoma, HM 2,56
CPI-0610 Clinical trial (I) 32 nmol/l MM, AML, neoplasms 57
Ten-010 Clinical trial (I) NS AML, myelodysplastic syndrome, 
solid tumors
58
OTX015 Clinical trial (II) 92 nmol/l Hematologic malignancies 59
RVX-208 Clinical trial (II) 200 nmol/l Atherosclerosis, ACS 2
PAC3 dimers Thielocin B1 Preclinical 20 nmol/l Cancer 60
JBIR-22 Preclinical 0.2 µmol/l Cancer 61
CRM1/cargo proteins Goniothalamin Preclinical 1.5 µmol/l (Breast) cancer 63
FRZ/DVL FJ9 Preclinical 29 µmol/l Cancer 65
Tcf-4/β-catenin PKF115-584 Preclinical 3.2 µmol/l (Colon) cancer 67
CGP0409090 Preclinical 8.7 µmol/l (Colon) cancer 68
Tcf-4/β-catenin/CBP ICG-001 Preclinical 3 µmol/l (Colon) cancer 69
Menin/MLL MI-2-2/MIV-6 Preclinical 20/85 nmol/l Leukemia 71,72
MI-463/MI-503 Preclinical 15.3/14.7 µmol/l Leukemia 73
The third column indicates the stage of investigation of each compound and in brackets are the phases of the clinical trials.
ACS, acute coronary syndrome; AML, acute myeloid leukemia; CBP, cyclic AMP response element-binding protein; CLL, chronic lymphocytic leukemia; CMML, chronic 
myelomonocytic leukemia; FRZ/DVL, Frizzled and Disheveled; HM, hematological malignancies; IAP, inhibitor of apoptosis protein; IC50, the concentration of a small 
molecule giving a half-maximal response; MDM2, murine double minute 2; ML, myelogenous leukemia; MLL, mixed lineage leukemia; MM, multiple myeloma; NS, 
not specified; PAC, proteasome assembling chaperone; PPI, protein–protein interaction; SLL, small lymphocytic lymphoma.
aPhase 2 clinical trials in combination with paclitaxel in patients with triple negative breast cancer.
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with Low PI), is released from the mitochondria into the cytosol 
in response to apoptotic stimuli (Figure 2). SMAC competes with 
caspase binding to BIR domains through its interaction with the 
AVPI tetrapeptide (Ala-Val-Pro-Ile) present in the N-terminal 
part of SMAC.31 Since the discovery of the SMAC protein in 2000, 
there has been an enormous interest by academic laboratories and 
pharmaceutical companies to design small molecule SMAC mimet-
ics.32 Seven SMAC mimetics have reached clinical trials and five 
molecules remain in clinical development. Current IAP inhibitors 
belong to two distinct classes, i.e., the monovalent and the bivalent 
inhibitors. The monovalent inhibitors, like LCL161 (Novartis, Basel, 
Switzerland),29,33 GDC-0917/CUDC-427, GDC-0152 (RG7419) 
(Genentech, San Francisco, CA/Curis, Lexington, MA),34,35 and 
SM-406/AT-406 (Wang lab/Ascenta Therapeutics, Malvern, PA),36 
were designed based on the AVPI peptide and have IC50 values in the 
nanomolar range. The bivalent inhibitors, such as Birinapant (TL-
32711) (Tetralogic Pharmaceuticals, Malvern, PA)37–39 and SM-1387 
(APG1387),40 are dimerized SMAC mimetics, which as homodimers 
bind simultaneously both XIAP’s BIR1/2 and BIR3 domains.
Bcl2 family. The B-cell lymphoma 2 (BCL2) family of proteins 
is composed of more than 20 members. Some members are anti-
apoptotic, like Bcl2, Bcl-XL, Bcl2l2, Mcl-1, whereas some others are 
proapoptotic such as Bax, Bak1, Bid, and Bcl2l11. The members of 
this family can engage in PPIs to modulate the intrinsic apoptotic 
pathway.41 The antiapoptotic Bcl2 members protect the cells against 
apoptosis by inhibiting the actions of the proapoptotic members 
(Figure 2). In some cancer types, the antiapoptotic members are 
overexpressed and the discovery of molecules that can bind to their 
hydrophobic grooves are predicted to induce apoptosis in cancer 
cells by antagonizing their protective effect. In 2005, researchers 
from the Abbott Laboratories (Chicago, IL), having utilized nuclear 
magnetic resonance-based screening and structure-based design, 
identified ABT-737, a potent small molecule inhibitor of Bcl2, Bcl-
XL, and Bcl2l2.42 Further optimization of ABT-737 in terms of phar-
macokinetics and efficacy via a fragment-based approach launched 
Navitoclax (ABT-263) as a potent antiapoptotic Bcl2 inhibitor, but 
its administration led to thrombocytopenia due to suppression 
of Bcl-xL.43–45 Later on, a Bcl2-specific version was designed, i.e., 
ABT-199 (RG7601). This compound is in phase 1 trials for chronic 
lymphocytic lymphoma or small lymphocytic lymphoma with an 
encouraging response rate of 84%.46,47 Another auspicious Bcl2 in-
hibitor is Obatoclax (GX015-070) from Gemin X Pharmaceuticals 
(Montreal, Quebec, Canada), an indole bipyrrole-containing drug, 
which is currently assessed in multiple phase 2 clinical trials. The 
attractive safety profile of Obatoclax offers the opportunity to treat 
many forms of cancer both as a single agent and in combination 
with current treatments. Advantageously, it is well tolerated, with-
out any evidence of immuno- or myelosuppression.48
Overexpression of Mcl-1 in cancer cells results in the seques-
tration of the proapoptotic Bak, Bax, Bad, and Bim, thus Mcl-1 
has also been subjected to inhibitor screens. Apart from natural 
compounds reported to inhibit this interaction in fluorescence 
resonance energy transfer assays,49 Varadarajan et al. introduced 
the small molecule TW-37 as a specific Mcl-1 inhibitor and as a 
lead compound for further synthetic programs.50 Recently, a series 
of indole-2-carboxylic acids have been described to bind Mcl-1 
selectively at nanomolar concentrations and to efficiently disrupt 
Mcl-1/Bim complexes in living cells. A-1210477, one of the most 
potent binders, induced apoptosis in Mcl-1-dependent cancer cell 
and showed synergistic effects when combined with Navitoclax.51 
A variety of other promising Mcl-1 inhibitor compounds that are 
currently being evaluated, including A*STAR compounds, MIM1, 
and Maritoclax, have been recently reviewed by Belmar and Fesik.52
Bromodomains. PPIs contributing to the formation of dynamic 
transcription complexes may determine chromatin modifications 
such as acetylation, hence controlling  the transcription fate of 
a specific gene locus. Bromodomains are epigenetic readers that 
recognize acetylated lysines (Kacs) on histones and mediate tran-
scription complexes to switch on genes. They share a conserved 
structure comprised by a left-handed bundle of four α-helices 
linked by diverse loop regions of variable charge and length. A 
hydrophobic pocket including a conserved asparagine and five 
water molecules recognizes the acetylated lysines. The interaction 
of this pocket with synthetic molecules has been explored in or-
der to control gene transcription.53 Accordingly, structure-based 
molecular modeling performed by Bradner’s laboratory at the 
Dana Farber Cancer Institute revealed the thienodiazepine (+)-
JQ1 compound which is specific for  bromodomain-containing 
protein 4 (BRD4) and has been used as an anticancer agent.54,55 
Other BRD4 inhibitors based on the (+)-JQ1 structure that 
are in clinical trials for cancer treatment include I-BET762 
(GSK525762) (Glaxosmithkline, Middlesex, UK),56 CPI-0610 
(Constellation Pharmaceutical, Cambridge, MA),57 Ten-
010 (Tensha Therapeutics, Cambridge, MA),58 and OTX015 
(OncoEthix, Lausanne, Switzerland).59 Additionally, RVX-208 is 
a quinazoline specific for BRD3 that is now in phase 2 clinical tri-
als for atherosclerosis.2
Oncology-related PPI targets in the preclinical stage. 
Proteasome assembling chaperone (PAC) 3 acts as a homodimer 
and plays an important role in proteasome formation. The fun-
gal metabolite Thielocin 1 (TB1) was identified through a frag-
ment complementation assay to inhibit the dimerization of PAC3 
and suppresses the growth of cancer cells.60 Another compound, 
named JBIR-22 and isolated from Verticillus sp., had a specific 
inhibitory activity on PAC3 homodimerization, hereby inhibiting 
the assembly of functional proteasomes.61
Protein shuttling between cytoplasmic and nuclear compart-
ments is critical for the accurate processing of signaling cascades. 
The transport of proteins from the nucleus to the cytoplasm by 
the exportin CRM1, which recognizes cargo proteins through a 
leucine-rich nuclear export signal, has also been targeted for inhi-
bition as an antitumor strategy.62 In the quest for analogous com-
pounds to anguinomycins, which are potent anticancer agents 
belonging to the leptomycin family, the natural product gonio-
thalamin was identified from plants of the genus Goniothalamus. 
Goniothalamin has been reported to induce cytotoxicity in breast 
cancer cells through disruption of the PPI between CRM1 and 
cargo proteins, leading to inhibition of nuclear export.63
Since the identification of Wnt1 as a proto-oncogene in a 
model of mouse breast cancer, the knowledge about this impor-
tant pathway has expanded. Perturbation of Wnt signaling is 
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associated with stimulation of proliferation and with prevention 
of apoptosis in a number of human cancers, which is reflected 
by an elevated transcriptional activity of β-catenin.64 A few PPIs 
involved in the Wnt pathway have been targeted for inhibition 
in order to limit the negative effect in cancer progression. The 
interaction between Frizzled (FRZ) and Disheveled (DVL) is 
one of the first steps in this pathway. Particularly promising for 
drug design is the observation that Wnt signaling associates with 
oncogenesis via the FRZ-7 receptor and both DVL and FRZ-7 are 
reported to be overexpressed in tumor cell lines. Indeed, inhibit-
ing the  FRZ-7/DVL interaction by the small molecule FJ9 induced 
apoptosis in human cancer cell lines and inhibited tumor growth 
in mouse xenograft (H460) models in vivo.65 The interaction of 
β-catenin with Tcf-4, further downstream in the Wnt pathway, has 
also been targeted in PPI inhibitor screens. About 7,000 natural 
compounds were tested in a high-throughput ELISA screen for 
their ability to inhibit the β-catenin/Tcf-4 interaction in the con-
text of colorectal cancer.66 Among them, two fungal compounds, 
PKF115-584 and CGP0409090, are interaction-specific inhibitors 
able to inhibit growth of colon cancer and adrenocortical67 and 
hepatocellular carcinomas.68 For the transcriptional activation of 
the  β-catenin/Tcf-4 complex, the coactivator cyclic AMP response 
 element-binding protein (CBP) is required. The small molecule 
ICG-001 binds specifically to CBP, leading to reduced transcrip-
tional activity of the complex. ICG-001 induces apoptosis in 
transformed colon cells and in mouse xenograft model of colon 
cancer.69
Inhibition of PPIs has also been a strategy for the management 
of leukemias. Menin functions as a critical oncogenic cofactor of 
mixed lineage leukemia (MLL) fusion proteins in the develop-
ment of acute leukemias, and inhibition of the menin interaction 
with MLL fusion proteins represents a very promising strategy to 
reverse their oncogenic activity. In an effort to identify small mol-
ecule inhibitors of the menin–MLL interaction, Grembecka et al. 
screened 49,000 small molecules using a fluorescence polariza-
tion assay and identified MI-2.70 Based on the crystal structures of 
menin with MI-2, more potent second-generation inhibitors were 
generated, namely MI-2-271 and MIV-6,72 that efficiently mimic 
the MLL peptide hot spots. Both compounds have binding activ-
ity in the nanomolar range and the preliminary in vitro data pro-
vided proof-of-concept for the development of PPI inhibitors to 
fight leukemia. In addition, two highly potent and orally bioavail-
able menin–MLL inhibitors (MI-463 and MI-503) were recently 
described that show profound effects in MLL leukemia cells and 
provide substantial survival benefit in vivo in mouse models of 
MLL leukemia.73
Targeting PPIs to combat infections by pathogens
The majority of viruses invade hosts by taking advantage of the 
cellular machinery to accomplish integration, replication, and 
survival. PPIs between viral and host proteins or among viral pro-
teins which are imperative for their maintenance in the host rep-
resent important clinical targets.
The homotetrameric retroviral integrase (IN) is an enzyme 
produced by retroviruses such as the human immunodeficiency 
virus, which integrates its genetic material into the DNA of the 
infected cell by catalyzing 3′-processing and strand transfer 
reactions. The human protein lens epithelium-derived growth 
factor (LEDGF/p75) is a cellular cofactor of IN that promotes 
viral integration by tethering the preintegration complex to the 
chromatin and protects IN from proteolytic degradation.74,75 
Intensive drug discovery efforts over the past years have vali-
dated the LEDGF-IN interaction as a druggable target for anti-
viral therapy and, through the use of structure-based approaches, 
have resulted in the design and synthesis of small molecule 
inhibitors, the  so-called LEDGINs. These molecules not only 
disrupt the interaction but also allosterically inhibit the cata-
lytic function of IN.76 The most potent LEDGF-IN inhibitors are 
 tert-Butoxy-(4-phenyl-quinolin-3-yl)-acetic acid (tBPQA) deriva-
tives, including the clinical compound BI 224436, which was similarly 
identified through structure-based drug design (Boehringer-
Ingelheim, Ingelheim, Germany/Gilead, Foster City, CA).77–79  
tBPQAs inhibit both early and late steps of the viral replication 
cycle, warranting their further clinical development.
A different strategy has been used for the inhibition of human 
papilloma virus replication, where the target is a PPI among viral 
proteins rather than between a viral and a host protein. Once 
entered into the host, human papilloma virus-11 requires the rep-
lication initiation factor E1 helicase to bind to the E2 transcription 
factor at specific DNA sites, and the small molecule compound 
BILH434 was identified to interrupt this interaction.80
Also PPIs involved in bacterial infections have been addressed 
as therapeutic targets. For example, FtsZ (a homologue of eukary-
otic tubulin) and ZipA (a membrane-anchored protein) interact 
to form the septal ring that mediates cell division and this PPI has 
been validated as a potential target in strategies to limit infection 
by Gram-negative bacteria. Compounds sharing the  indolo[2,3-a]
quinolizin-7-one structure have been shown to inhibit this inter-
action in in vitro assays.81 Additionally, an nuclear magnetic 
 resonance-based fragment screening approach revealed a hit 
series able to inhibit the FtsZ/ZipA interaction through binding 
the C-terminal domain of ZipA.82
PPIs involved in neuronal diseases
Amyloid β (Aβ), and specifically Aβ40 and Aβ42, constitutes 
the main component of the amyloid plaques found in the brains 
of  Alzheimer patients.83 The essential factors generating of Aβ 
are β- and γ-secretase, which are primary amyloidogenic prote-
ases. The initial cleavage of amyloid precursor protein (APP) is 
mediated by β-secretase and results in two products, an amino-
terminal fragment of APP, sAPPb and a membrane embedded 
 carboxy-terminal fragment, C99. C99 is the immediate sub-
strate for γ-secretase, resulting in the generation of Aβ40 and 
Aβ42, which contribute to the progression of Alzheimer’s dis-
ease.84 Inhibition of the interaction between γ-secretase and the 
APPs can lead to new therapeutic opportunities for the treat-
ment of Alzheimer’s disease. Different approaches were fol-
lowed to design γ-secretase inhibitors, including transition state 
analogues, α-helical peptide-based inhibitors and nontransi-
tion state analogues.85 The small molecule compound LY450139 
or Semagacestat is a benzolactam γ-secretase inhibitor, which 
entered clinical trials in 2005. Unfortunately, the results from 
phase 3 clinical trials showed that Semagacestat was associated 
with impaired lymphocyte differentiation and an increased risk 
712 www.moleculartherapy.org vol. 24 no. 4 apr. 2015
Official journal of the American Society of Gene & Cell Therapy
Modulation of Protein–Protein Interactions
for skin cancer, so it was withdrawn.86 As secretase activity is still 
in the center of research interest, control of β-secretase gradually 
gains attention for the same therapeutic purpose.87
Parkinson’s disease is the second most common neurodegenera-
tive disorder in most Western countries.88 Experimental data sug-
gest that an important factor driving this pathology is the misfolding 
and oligomerization of the protein α-synuclein, which consequently 
forms a series of self-associating β-pleated sheets that spontaneously 
form aggregates called “Lewy bodies.”89,90 Therefore, inhibitors of the 
aggregation of α-synuclein are in the center of scientific interest and 
several inhibitors have been identified.91,92 An intriguing finding is 
that catecholamines are capable of inhibiting α-synuclein aggrega-
tion93 while still constitutes an area of active research for the develop-
ment of novel therapeutics in Parkinson’s disease.
Figure 3 Modulation of liganded receptors with small molecules. (a) PPI inhibitors of liganded receptors. Small molecules designed to inhibit 
cytokine signaling of IL-17 and IL-2 through their respective receptors IL-17R and IL-2R. The GR/Hsp90 inhibition by silibinin is involved in Cushing’s 
syndrome and the interaction of ICAM1 with LFA-1 is targeted by lifitegrast to obtain immunosuppression. (b) Beneficial effects of stabilization of 
14-3-3 protein interaction with GR or ER. The chemical structures of the depicted molecules are provided except for the structure of Ensemblins, 
which is not publicly available. ER, estrogen receptor; GR, glucocorticoid receptor; IL, interleukin; PPI, protein–protein interaction.
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Modulation of PPIs of liganded receptors
Activated receptors control an array of physiological functions 
upon binding of their respective ligands. Numerous pathological 
conditions have been attributed to the deregulation of liganded 
receptor-dependent signaling pathways. This deregulation can be 
mediated partially by PPIs that alter the receptor-dependent signal-
ing cascades; hence their control has attracted scientific attention. 
A few small molecules have been reported for their in vitro ability 
to interfere with activated receptors. Cushing’s disease is a neuro-
endocrine condition caused by partially  glucocorticoid-resistant 
corticotroph adenomas leading to hypercortisolism.94 The effects 
of glucocorticoids are mediated by the glucocorticoid receptor. 
In  its unliganded form, glucocorticoid receptor exists in a com-
plex with chaperoning proteins, like Hsp90, which play a signifi-
cant role in the proper conformation of the receptor. Silibinin 
binds to the C-terminal part of Hsp90, inhibiting its interaction 
with glucocorticoid receptor. In an allograft mouse model, admin-
istration of silibinin alleviated symptoms of Cushing’s syndrome, 
indicating that a reduced response to glucocorticoids can be over-
come pharmacologically with selective Hsp90 inhibitors.95
The interaction between interleukin-17 (IL-17) and its recep-
tor has also been under investigation for inhibition since IL-17 
is a potent proinflammatory cytokine involved in the pathogen-
esis of multiple inflammatory diseases such as psoriasis, rheu-
matoid arthritis, and Crohn’s disease.96 Ensemble Therapeutics 
has identified a series of unique small molecule macrocycles, or 
Ensemblins that are antagonists of IL-17. In 2012, this company 
announced positive preclinical oral efficacy data with its first-
in-class small molecule IL-17 antagonists. Similarly, an nuclear 
magnetic  resonance-based approach yielded Ro26-455, a compet-
itive inhibitor of IL-2 for binding to its receptor IL-2Ra, with an 
IC50 of 3 mM.97 Further evolvement of the Ro26-4550 scaffold by 
 fragment-based methods into a more potent and drug-like inhibi-
tor of IL-2:IL-2Ra resulted in the generation of SP4206.98 However, 
more functional studies are needed to evaluate the significance 
and efficiency of this molecule in interfering with IL-2 signal-
ing.99 An  analogous strategy was followed for targeting tumor 
necrosis factor signaling. Some molecules that interfere with the 
tumor necrosis factor/tumor necrosis factor receptor interaction 
are under preclinical investigation.100,101 Among the scientific 
advances for immunoregulation, the PPI inhibitor lifitegrast 
(SAR1118) plays a predominant role. Lifitegrast inhibits the inter-
action between LFA-1 (Cd11a/α2, CD18/β2) and ICAM1. LFA-1 
is a β2 integrin receptor found on leukocytes and involved in T-cell 
activation through binding to its ligand ICAM1.102 Lifitegrast suc-
cessfully passed clinical trials for treatment of inflammatory dry 
eye syndrome,103 resulting in a drug application being filed for this 
new inhibitor in the beginning of 2015 (Figure 3a).
Table 2 PPI inhibitors for different pathological conditions
PPI Small molecule Investigation stage Binding affinity (IC50) Disease condition Reference
LEDGF/integrase tBPQA (BI 224436) Clinical trial (I) 20 nmol/l HIV infection 77–79
HPV11 E1-E2 BILH434 Preclinical 40 nmol/l HPV infection 80
ZipA/FtsZ Pyridylpyrimidine indolo 
[2,3-a] quinolizin-7-one
Preclinical NS Infection by Gram (−) 
bacteria
81,82
γ-secretase/amyloid 
precursor
Semagacestat Clinical trial (III)  
(removed)
10.9 nmol/l Alzheimer disease 86
GR/Hsp90 Silibinin Preclinical 40 µmol/l Cushing’s syndrome 95
IL-7/IL-17R Ensemblins Preclinical 3 nmol/l Inflammatory disorders 96
IL-2/IL-2Rα SP4206 Preclinical 60 nmol/l Inflammatory disorders 98,99
LFA-1/ICAM1 Lifitegrast Approved 9 nmol/l Dry eye syndrome 2,103
GR, glucocorticoid receptor; HIV, human immunodeficiency virus; HPV, human papilloma virus; IC50, the concentration of a small molecule giving a half-maximal 
response; IL, interleukin; LEDGF, lens epithelium-derived growth factor; NS, not specified; PPI, protein–protein interaction; tBPQA, tert-Butoxy-(4-phenyl-quinolin-
3-yl)-acetic acid.
Figure 4 PPI stabilizers in cancer treatment and in the modulation 
of immunosuppression. (a) Paclitaxel is a representative allosteric PPI 
stabilizer that preserves tubulin formation. (b) FK506 and rapamycin are 
potent immunosuppressants acting as direct stabilizers of protein inter-
actions with FKBP12. PPI, protein–protein interaction.
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THE “YANG” FACE OF PPIs – STABILIZATION OF 
BENEFICIAL PPIs
The “other side” of PPI control is stabilization. Small molecule PPI 
stabilizers act through two distinct mechanisms of action. First, 
allosteric stabilizers interact with one of the interaction partners 
of the complex, increasing the mutual affinity binding of the inter-
acting proteins. Second, direct stabilizers may interact within the 
interfacial surface of a protein complex, creating contacts with the 
participating partners, similarly leading to an increased binding 
affinity (Table 2).4
PPI stabilization as an anticancer treatment
One of the most common PPI stabilizers widely used in the clinic 
as an anticancer agent is the Taxus brevifolia-derived paclitaxel, 
which interferes with the normal breakdown of microtubules 
during cell division.104 Paclitaxel and other compounds of this 
category induce cell cycle arrest by modulating microtubules’ 
polymerization status.105 Microtubules consist of α- and β-tubulin 
and paclitaxel binds with high affinity to a hydrophobic pocket 
located on β-tubulin, thereby stabilizing polymerized microtu-
bule structures in an allosteric fashion (Figure 4a).106
14-3-3 proteins have also been described to participate in 
diverse cancers, neurodegenerative diseases, or virulence of human 
pathogenic organisms.107–109 Due to their versatile mode of action, 
these proteins constitute a novel target class for pharmacologi-
cal intervention by either stabilizing or inhibiting 14-3-3 PPIs. 
In a number of cases, 14-3-3 proteins have been shown to sup-
port the stability and bioavailability of their interaction partners 
such as TASK3.110 Dysregulation of TASK3 has been linked to 
cancer, inflammation, and epilepsy,111 hence stabilization of the 
14-3-3 (β and ε isoforms)/TASK3 interaction could prove thera-
peutically promising. Furthermore, the stabilization of estrogen 
receptor α (ERα) binding to 14-3-3β has been reported to have 
anticancer effects.112 Fusicoccin directly binds to the interface rim 
of the 14-3-3σ/ERα and stabilizes this interaction (Figure  3b). 
Fusicoccin treatment leads to diminished estradiol-mediated ERα 
dimerization, limitation of ERα binding to chromatin, and down-
stream gene activation as well as decreased cell proliferation.113 
Current breast cancer treatments are based on the suppression 
of the transcriptional potency of ERα by aromatase inhibitors or 
antiestrogens. Due to the onset of resistance of patients to these 
treatments, there is an urgent need for alternative therapeutics. 
Inhibition of ERα activity through stabilization of its interaction 
with 14-3-3 represents a new strategy for drug development in the 
field of breast cancer (Table 3).
Stabilizers of PPIs acting as immunosuppressants
Two directly stabilizing molecules, rapamycin (Sirolimus) and 
FK506 (Tacrolimus), are well-known immunosuppressants in 
the clinic. Although they have considerably different structures, 
they share a remarkably common mechanism of action. FK506 
and rapamycin stabilize the interactions between FKBP12/pro-
tein phosphatase calcineurin and FKBP12/mTOR (mammalian 
target of rapamycin), respectively. Interestingly, initially FK506 
and rapamycin bind with high affinity to FKBP12, which is an 
immunophilin.114 In a next step, FK506/FKBP12 and rapamy-
cin/FKBP12 bind to calcineurin and mTOR, respectively, via the 
newly formed interface. This results in suppression of the catalytic 
activity of these enzymes (Figure 4b). Of note, in the absence of 
FK506 and rapamycin, FKBP12 is not able to interact with calci-
neurin115 or with mTOR.116 Rapamycin117 and FK506118 have been 
investigated as immunosuppressive agents for treatment of trans-
plant patients in different clinical trials.
Mizoribine is an imidazole nucleoside with immunosuppres-
sive activity. Mizoribine has been approved in Japan for combina-
torial therapy with glucocorticoids in lupus nephritis, rheumatoid 
arthritis, or after renal transplantation.119 A possible mechanism 
of mizoribine is the enhancement of the interaction of 14-3-3η 
with the glucocorticoid receptor leading to enhanced activity of 
the receptor and subsequent increased immunosuppression120 
(Figure 3b).
CONCLUSIONS AND FUTURE PERSPECTIVES
Natural products like taxanes and rapamycin, which were dis-
covered in the late 90s as potent stabilizers of PPIs, raised initial 
enthusiasm for small molecule modulation of PPIs as a thera-
peutic rationale. During the next decade, the advance of “omics” 
technologies, greatly expanding our knowledge of genes, proteins, 
and their interactions, highlighted the central importance of PPI 
networks both towards enhancing our basic understanding of cel-
lular processes and as a vast source of potential drug targets, fur-
ther increasing interest in PPI-targeted drug discovery. Yet, at the 
same time high-resolution structures revealed that PPI interfaces 
are often made up of large shallow surfaces which were thought to 
be difficult, if not impossible, to interfere with, significantly lower-
ing confidence in the approach.
Table 3 PPI stabilizers for the control of immunosuppression and cancer progression
PPI Small molecule Investigation stage Binding affinity (IC50) Disease condition Reference
FKBP12/calcineurin FK506 Approved 37 nmol/l Immunosuppressant after transplantation 115,118
FKBP12/mTOR Rapamycin Approved 0.2 nmol/l Immunosuppressant after transplantation 116,117
α/β tubulin Paclitaxel Approved 2.5 nmol/l ovarian, breast, lung, bladder, prostate, 
esophageal cancer
105,106
14-3-3η/GR Mizoribine Approved NS Lupus nephritis, active rheumatoid, 
rheumatoid arthritis
119,120
14-3-3/ERα Fusicoccin Preclinical NS (Breast) cancer 112,113
ER, estrogen receptor; GR, glucocorticoid receptor; IC50, the concentration of a small molecule giving a half-maximal response; mTOR, mammalian target of 
 rapamycin; NS, not specified; PPI, protein–protein interaction.
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The cases of inhibitors and stabilizers described in this review 
however clearly illustrate the potential of PPIs in drug develop-
ment. Novel small molecules targeting specific PPIs have entered 
clinical trials, and in some cases already resulted in new therapeu-
tics or optimized treatments.
Looking at the technologies that lead to these successful pro-
grams, it is striking to note the variety of discovery approaches. 
The huge diversity in PPIs and in the characteristics of their 
interfaces clearly precludes a one-fits-all approach. The reported 
progress in PPI drug discovery should be attributed at least partly 
to the growing availability of a varied and complementary set of 
both in vitro and in silico screening approaches from which can 
be drawn depending on the nature of the PPI target.121 Also at the 
compound side, there should be a proper match with the nature of 
the target. An often-cited caveat is the fact that classic small mol-
ecule libraries applied in high-throughput screening campaigns 
consist mainly of small, simple, and flat structures, whereas suc-
cessful disruption of a PPI interface generally requires larger and 
more complex molecules. Studies aimed at determining common 
features among successful PPI inhibitors yielded a number of 
rational design principles that can be used to compile PPI-specific 
compound collections which should increase hit rates in PPI 
inhibitor screens.122
In addition to small molecules, also peptides were shown to 
be promising tools for targeting PPIs. Yet, despite the exciting pre-
liminary in vitro data, the use of peptides as therapeutics has been 
hampered by fast renal clearance, poor metabolic stability, and 
biodegradability. Nevertheless, different strategies were applied 
to improve plasma half-lives of these therapeutic peptides, result-
ing in potent PPI modulators, for instance for Bcl2, caspases, and 
ERα.123 Particularly encouraging is the case of the “stapled” pep-
tides that reactivate the p53 pathway by binding and inhibiting 
HDM2 and HDMX. These entered clinical trials in 2014.124
Traditionally, drug design has been directed towards targets 
containing well-defined binding pockets such as enzymes, nuclear 
receptors, and ion channels. However, our increased understand-
ing of PPIs, their interfaces, and how to interfere with these open 
up new horizons for drug development. Resolving PPI modula-
tion currently constitutes an area of intense research and numer-
ous protein complexes await further investigation as potential new 
therapeutic agents.
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